Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands

被引:10
作者
Broers, Merel C. [1 ]
Wilde, Marcel [2 ]
Lingsma, Hester F. [3 ]
Lei, Johan [2 ]
Verhamme, Katia M. C. [2 ,4 ,5 ]
Jacobs, Bart C. [1 ,6 ]
机构
[1] Erasmus MC, Dept Neurol, Univ Med Ctr Rotterdam, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands
[2] Erasmus MC, Dept Med Informat, Univ Med Ctr Rotterdam, Rotterdam, Netherlands
[3] Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, Rotterdam, Netherlands
[4] Univ Ghent, Fac Pharmaceut Sci, Dept Bioanal, Pharmaceut Care Unit, Ghent, Belgium
[5] Onze Lieve Vrouw Hosp, Dept Infect Control & Epidemiol, Aalst, Belgium
[6] Erasmus MC, Dept Immunol, Univ Med Ctr Rotterdam, Rotterdam, Netherlands
关键词
chronic inflammatory demyelinating polyradiculoneuropathy; CIDP; epidemiology; incidence; prevalence; DIABETES-MELLITUS; POLYNEUROPATHY; CIDP; NEUROPATHIES;
D O I
10.1111/jns.12502
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare but disabling disorder that often requires long-term immunomodulatory treatment. Background incidence rates and prevalence and risk factors for developing CIDP are still poorly defined. In the current study, we used a longitudinal population-based cohort study in The Netherlands to assess these rates and demographic factors and comorbidity associated with CIDP. We determined the incidence rate and prevalence of CIDP between 2008 and 2017 and the occurrence of potential risk factors in a retrospective Dutch cohort study using the Integrated Primary Care Information (IPCI) database. Cases were defined as CIDP if the diagnosis of CIDP was described in the electronic medical file. In a source population of 928 030 persons with a contributing follow-up of 3 525 686 person-years, we identified 65 patients diagnosed with CIDP. The overall incidence rate was 0.68 per 100 000 person-years (95% CI 0.45-0.99). The overall prevalence was 7.00 per 100 000 individuals (95% CI 5.41-8.93). The overall incidence rate was higher in men compared to woman (IRR 3.00, 95% CI 1.27-7.11), and higher in elderly of 50 years or older compared with people <50 years of age (IRR 17 95% CI 4-73). Twenty percent of CIDP cases had DM and 9% a co-existing other auto-immune disease. These background rates are important to monitor changes in the frequency of CIDP following infectious disease outbreaks, identify potential risk factors, and to estimate the social and economic burden of CIDP.
引用
收藏
页码:182 / 188
页数:7
相关论文
共 50 条
  • [21] Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy
    Rezania, K
    Gundogdu, B
    Soliven, B
    FRONTIERS IN BIOSCIENCE, 2004, 9 : 939 - 945
  • [22] Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
    Hughes, Richard A. C.
    Mehndiratta, Man Mohan
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (08):
  • [23] Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy
    Van den Bergh, Peter Y. K.
    van Doorn, Pieter A.
    Jacobs, Bart C.
    Querol, Luis
    Bunschoten, Carina
    Cornblath, David R.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (01) : 4 - 8
  • [24] Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
    Hughes, Richard A. C.
    Mehndiratta, Man Mohan
    Rajabally, Yusuf A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [25] Usefulness and prognostic value of diagnostic tests in patients with possible chronic inflammatory demyelinating polyradiculoneuropathy
    Thirouin, Jeanne
    Petiot, Philippe
    Antoine, Jean-Christophe
    Andre-Obadia, Nathalie
    Convers, Philippe
    Gavoille, Antoine
    Bouhour, Francoise
    Rheims, Sylvain
    Camdessanche, Jean-Philippe
    MUSCLE & NERVE, 2022, 66 (03) : 304 - 311
  • [26] Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
    Adrichem, Max E.
    Lucke, Ilse M.
    Vrancken, Alexander F. J. E.
    Goedee, H. Stephan
    Wieske, Luuk
    Dijkgraaf, Marcel G. W.
    Voermans, Nicol C.
    Notermans, Nicolette C.
    Faber, Catharina G.
    Visser, Leo H.
    Kuitwaard, Krista
    van Doorn, Pieter A.
    Merkies, Ingemar S. J.
    de Haan, Rob J.
    van Schaik, Ivo N.
    Eftimov, Filip
    BRAIN, 2022, 145 (05) : 1641 - 1652
  • [27] Outcome measures in pediatric chronic inflammatory demyelinating polyradiculoneuropathy
    Guttikonda, Apoorva
    Ahmad, Ghazal
    Goyal, Parul
    Xiang, Yijin
    Johnson, Laura Michelle
    Gillespie, Scott
    Carvell, Kimberly T.
    Butera, Robert
    Verma, Sumit
    MUSCLE & NERVE, 2024, 69 (05) : 580 - 587
  • [28] Does the chronic inflammatory demyelinating polyradiculoneuropathy due to secondary cause differ from primary
    Wadwekar, Vaibhav
    Kalita, Jayantee
    Misra, Usha Kant
    NEUROLOGY INDIA, 2011, 59 (05) : 16 - 20
  • [29] Chronic inflammatory demyelinating polyradiculoneuropathy with tumefactive central demyelination
    Krivickas, LS
    Hochberg, FH
    Freeman, S
    MUSCLE & NERVE, 2006, 33 (02) : 283 - 288
  • [30] Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases
    Roux, Thomas
    Debs, Rabab
    Maisonobe, Thierry
    Lenglet, Timothee
    Delorme, Cecile
    Louapre, Celine
    Leblond, Veronique
    Viala, Karine
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 235 - 240